title: Cysticlean® a highly pac standardized content in the prevention of recurrent urinary tract infections: an observational, prospective cohort study.
abstract: BACKGROUND
  The present study was aimed at determining the prophylactic efficacy of American cranberry (AC) extract (Cysticlean®) in women with recurrent symptomatic postcoital urinary tract infections (PCUTI), non-consumer of AC extract in the past 3 months before inclusion, and to determine changes in their quality of life (QoL).
  
  
  METHODS
  This was a single center, observational, prospective study in a total of 20 women (mean age 35.2 years; 50.0% were married). Patients were followed up for 3 and 6 months during treatment.
  
  
  RESULTS
  The number of PCUTIs in the previous 3 months prior to start the treatment with Cysticlean® was 2.8±1.3 and it was reduced to 0.2±0.5 at Month 6 (P<0.0001), which represent a 93% improvement. At baseline, the mean score on the VAS scale (range from 0 to 100) for assessing the QoL was 62.4±19.1, increasing to 78.2±12.4 at Month 6 (P=0.0002), which represents a 20% improvement. All patients had an infection with positive urine culture at baseline, after 6 months there were only 3 symptomatic infections (P<0.001). The most common bacterium was Escherichia coli.
  
  
  CONCLUSIONS
  Prophylaxis with American cranberry extract (Cysticlean®) could be an alternative to classical therapies with antibiotics. Further studies are needed to confirm results obtained in this pilot study.
authors.forename: Francisco
authors.initials: F
authors.lastname: Sánchez Ballester
authors.forename: Vicente
authors.initials: V
authors.lastname: Ruiz Vidal
authors.forename: Emilio
authors.initials: E
authors.lastname: López Alcina
authors.forename: Cristina
authors.initials: C
authors.lastname: Domenech Perez
authors.forename: Eva
authors.initials: E
authors.lastname: Escudero Fontano
authors.forename: Ana
authors.initials: A
authors.lastname: Oltra Benavent
authors.forename: Ana
authors.initials: A
authors.lastname: Montoliu García
authors.forename: Marco
authors.initials: M
authors.lastname: Sobrón Bustamante
mesh_terms: D000293:Adolescent; D000328:Adult; D000900:Anti-Bacterial Agents / Q000592:standards / Q000627:therapeutic use; D001424:Bacterial Infections / Q000188:drug therapy* / Q000517:prevention & control* / Q000523:psychology; D015331:Cohort Studies; D003075:Coitus; D019587:Dietary Supplements / Q000592:standards; D005260:Female; D006801:Humans; D008875:Middle Aged; D044945:Proanthocyanidins / Q000592:standards / Q000627:therapeutic use*; D011446:Prospective Studies; D011788:Quality of Life / Q000523:psychology*; D055502:Secondary Prevention; D013030:Spain; D016896:Treatment Outcome; D014481:United States; D014552:Urinary Tract Infections / Q000188:drug therapy* / Q000517:prevention & control* / Q000523:psychology; D055815:Young Adult
chemical_list: D000900:Anti-Bacterial Agents; C554859:Cysticlean; D044945:Proanthocyanidins